83.1. Leukemia: Acute Myeloid Leukemia

Authors

Emerging Prognostic Factors for Clinical Care

<table>
<thead>
<tr>
<th>Factor</th>
<th>Definition</th>
<th>Clinical Significance</th>
<th>Level of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clearance of mutations after induction therapy</td>
<td>Assessed by exome or whole genome sequencing</td>
<td>Patients with persistence of mutations had shorter remissions than patients without persistence</td>
<td>III¹</td>
</tr>
</tbody>
</table>

Risk Assessment Models
The AJCC recently established guidelines that will be used to evaluate published statistical prediction models for the purpose of granting endorsement for clinical use.² Although this is a monumental step toward the goal of precision medicine, this work was published only very recently. Therefore, the existing models that have been published or may be in clinical use have not yet been evaluated for this cancer site by the Precision Medicine Core of the AJCC. In the future, the statistical prediction models for this cancer site will be evaluated, and those that meet all AJCC criteria will be endorsed.

Recommendations for Clinical Trial Stratification
The authors have not provided any recommendations for clinical trial stratification at this time.

Bibliography